The news is directly about Acurx Pharmaceuticals and is likely to influence investor sentiment. The lowering of the price target might be seen as a negative signal, but the maintained 'Buy' rating indicates continued confidence in the company's prospects. The net impact on the stock price is uncertain in the short term.